Amgen stock heads into ACR presentation with dazodalibep data

Published on 11/10/2026 at 13:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock faces a key clinical-data event as the company prepares to present Phase 3 dazodalibep results at ACR Convergence. The update is scheduled for Wednesday.

Amgen pipeline milestone ahead

Amgen will present late-breaking Phase 3 OASIZ-301 results for dazodalibep at ACR Convergence on Wednesday, November 11.
Both dosing regimens reduced systemic disease activity versus placebo at Week 48.
A separate Phase 3 study for patients with high symptom burden is expected to complete in the fourth quarter of 2026.

Amgen, US0311621009, Illustration mit AI erstellt.

Amgen is approaching a closely watched clinical milestone for its autoimmune pipeline. The company is scheduled to present late-breaking Phase 3 results for dazodalibep at the American College of Rheumatology Convergence on Wednesday, November 11, according to an Amgen investor-relations release dated October 27 and updated November 2.

Amgen will discuss the Phase 3 OASIZ-301 study in adults with Sjogren disease and moderate-to-severe systemic disease activity. The oral presentation is scheduled for 8:45 a.m. Eastern Time and is listed as a late-breaking abstract. The program gives investors a near-term readout on a potential addition to Amgen's autoimmune portfolio.

Phase 3 results set clinical test

The OASIZ-301 study met its primary endpoint, with both dazodalibep regimens producing statistically significant improvements in systemic disease activity at Week 48. The least-squares mean change in the ESSDAI score was minus 5.6 points for the 1,500-milligram regimen administered every four weeks and minus 5.2 points for the 3,000-milligram regimen administered every 12 weeks. The placebo group recorded a minus 3.8-point change.

Compared with placebo, the differences were 1.8 points for four-week dosing and 1.4 points for 12-week dosing. Amgen said the treatment effect was visible as early as Week 4. The release also said treatment-emergent adverse events, serious adverse events and discontinuations occurred at similar rates across the study groups.

The four-week regimen also improved patient-reported dryness, a key secondary endpoint. The ESSPRI dryness score declined by 2.50 points from baseline, compared with 1.33 points for placebo, while the DASPRI dryness score fell by 1.98 points versus 1.05 points for placebo. The presentation will provide a fuller view of the trial results and their potential relevance for further development.

Next pipeline checkpoint remains

Amgen is also running OASIZ-303, a separate Phase 3 study in patients with high symptom burden and low systemic disease activity. The company expects that trial to complete in the fourth quarter of 2026. OASIZ-304 is evaluating long-term safety and tolerability in eligible participants from OASIZ-301 and OASIZ-303.

Amgen stock traded at 416.13 euros on Lang & Schwarz at 13:31 CET on Tuesday, November 10, 2026.